Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, has appointed Mary Rozenman, PhD, as senior vice president, corporate and commercial development, and Mike Holfinger, PhD, as vice president, manufacturing. The appointments came as ARC prepares for its upcoming Phase III clinical trial of the company’s lead product, AR 101, a standardized pharmaceutical-grade peanut protein formulation for treating peanut allergy via characterized oral desensitization immunotherapy. The company recently announced the completion of an $80 million Series B financing, which will support the Phase II trial along with the initiation of clinical trials for treatment of egg and milk allergies.
Dr. Rozenman joins ARC from Longitude Capital, where she was a vice president focused on biotechnology investments and was an observer on ARC’s board of directors. She was previously an associate principal in the healthcare and corporate finance practices at McKinsey & Company, where she advised senior management of pharmaceutical companies on a range of strategic and operational issues across marketing, sales and corporate development, and led the firm’s global Biosimilars practice.
Dr. Holfinger joins ARC from Alexza Pharmaceuticals, where he was vicepPresident, manufacturing and Global supply chain management. He has more than two decades of experience in process development and global manufacturing of commercial products, including seven years with Affymax, where he most recently served as vice president, manufacturing and CMC development, and 14 years with Pfizer, Pharmacia and Upjohn.
Source: Allergen Research Corporation